7MK7 image
Entry Detail
PDB ID:
7MK7
Keywords:
Title:
Augmentor domain of augmentor-beta
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-04-21
Release Date:
2021-11-24
Method Details:
Experimental Method:
Resolution:
2.43 Å
R-Value Free:
0.27
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:ALK and LTK ligand 1,Maltodextrin-binding protein
Mutations:D108A, K109A, E198A, N199A, A241H, K245H, K265A, A338V, I343V
Chain IDs:A, B
Chain Length:421
Number of Molecules:2
Biological Source:Homo sapiens, Escherichia coli
Peptide-like Molecules
PRD_900001
Primary Citation
Structural basis for ligand reception by anaplastic lymphoma kinase.
Nature 600 148 152 (2021)
PMID: 34819665 DOI: 10.1038/s41586-021-04141-7

Abstact

The proto-oncogene ALK encodes anaplastic lymphoma kinase, a receptor tyrosine kinase that is expressed primarily in the developing nervous system. After development, ALK activity is associated with learning and memory1 and controls energy expenditure, and inhibition of ALK can prevent diet-induced obesity2. Aberrant ALK signalling causes numerous cancers3. In particular, full-length ALK is an important driver in paediatric neuroblastoma4,5, in which it is either mutated6 or activated by ligand7. Here we report crystal structures of the extracellular glycine-rich domain (GRD) of ALK, which regulates receptor activity by binding to activating peptides8,9. Fusing the ALK GRD to its ligand enabled us to capture a dimeric receptor complex that reveals how ALK responds to its regulatory ligands. We show that repetitive glycines in the GRD form rigid helices that separate the major ligand-binding site from a distal polyglycine extension loop (PXL) that mediates ALK dimerization. The PXL of one receptor acts as a sensor for the complex by interacting with a ligand-bound second receptor. ALK activation can be abolished through PXL mutation or with PXL-targeting antibodies. Together, these results explain how ALK uses its atypical architecture for its regulation, and suggest new therapeutic opportunities for ALK-expressing cancers such as paediatric neuroblastoma.

Legend

Protein

Chemical

Disease

Primary Citation of related structures